GLYC - GLYCOMIMETICS INC

QQQ $ 481.15 $ 6.24 (1.31 %)

DIA $ 409.09 $ 2.37 (0.58 %)

SPY $ 559.11 $ 5.30 (0.96 %)

TLT $ 97.90 $ 0.45 (0.46 %)

GLD $ 231.62 $ -0.38 (-0.16 %)

Previous Close

$ 0.1702

Open

Bid

$ 0.17 x 600

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 0.17 - $ 3.53

Volume

2,732,095

Average Volume

Market Cap

10.98M

Beta (5Y Monthly)

$ 1.71

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	03-27-2024	12-31-2023	10-K
4	11-03-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	05-03-2023	03-31-2023	10-Q
7	03-29-2023	12-31-2022	10-K
8	11-09-2022	09-30-2022	10-Q
9	08-03-2022	06-30-2022	10-Q
10	04-28-2022	03-31-2022	10-Q
11	03-03-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-03-2021	03-31-2021	10-Q
15	03-02-2021	12-31-2020	10-K
16	11-06-2020	09-30-2020	10-Q
17	07-31-2020	06-30-2020	10-Q
18	05-01-2020	03-31-2020	10-Q
19	02-28-2020	12-31-2019	10-K
20	11-07-2019	09-30-2019	10-Q
21	08-01-2019	06-30-2019	10-Q
22	05-02-2019	03-31-2019	10-Q
23	03-06-2019	12-31-2018	10-K
24	11-02-2018	09-30-2018	10-Q
25	08-09-2018	06-30-2018	10-Q
26	05-03-2018	03-31-2018	10-Q
27	03-06-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-03-2017	06-30-2017	10-Q
30	05-08-2017	03-31-2017	10-Q
31	03-01-2017	12-31-2016	10-K
32	11-04-2016	09-30-2016	10-Q
33	08-04-2016	06-30-2016	10-Q
34	05-04-2016	03-31-2016	10-Q
35	02-29-2016	12-31-2015	10-K
36	11-12-2015	09-30-2015	10-Q
37	08-06-2015	06-30-2015	10-Q
38	05-05-2015	03-31-2015	10-Q
39	03-16-2015	12-31-2014	10-K
40	10-31-2014	09-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

GlycoMimetics Anticipates Recognizing Abou...
07/30/2024 19:58:37

- SEC Filing

TD Cowen Downgrades GlycoMimetics to Hold
07/26/2024 18:45:01

TD Cowen analyst Boris Peaker downgrades GlycoMimetics (NASDAQ:GLYC) from Buy to Hold.

GlycoMimetics To Conduct Additional Clinic...
07/25/2024 13:01:44

On June 21, GlycoMimetics Got Notice From ...
06/26/2024 20:35:46

- SEC Filing

Why GlycoMimetics Stock is Trading Higher ...
06/25/2024 16:06:19

On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305 thousand shares in the company.

GlycoMimetics Form 4 Filing Shows CMO Edwi...
06/24/2024 20:35:28

- SEC Filing

1m-bet-on-this-penny-stock-check-out-these-4-stocks-under-2-insiders-are-aggressively-buying

$1M Bet On This Penny Stock? Check Out The...
06/21/2024 12:22:05

HC Wainwright & Co. Reiterates Neutral on ...
06/04/2024 20:12:22

HC Wainwright & Co. analyst Edward White reiterates GlycoMimetics (NASDAQ:GLYC) with a Neutral.

$glycomimetics-shares-detailed-results-from-its-pivotal-phase-3-study-of-uproleselan-in-relapsedrefractory-acute-myeloid-leukemia$

GlycoMimetics Shares Detailed Results From...
06/04/2024 11:09:16

Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinica...

$glycomimetics-to-host-leader-event-to-review-results-from-pivotal-phase-3-study-of-uproleselan-in-relapsedrefractory-acute-myeloid-leukemia-on-june-4-2024$

GlycoMimetics To Host Leader Event To Revi...
05/29/2024 20:03:25

GlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based the...